본문으로 건너뛰기
← 뒤로

Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.

1/5 보강
CEN case reports 2025 Vol.14(5) p. 768-773
Retraction 확인
출처

Takami J, Nakano Y, Harada E, Nakakuma S, Kawamoto R, Ito E

📝 환자 설명용 한 줄

Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Takami J, Nakano Y, et al. (2025). Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.. CEN case reports, 14(5), 768-773. https://doi.org/10.1007/s13730-025-01014-0
MLA Takami J, et al.. "Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.." CEN case reports, vol. 14, no. 5, 2025, pp. 768-773.
PMID 40637925 ↗

Abstract

Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers. Although renal injury due to FTD/TPI is rare, its renal effects have not been well documented. We present the case of a 74-year-old man with metastatic colon cancer who developed nephrotic syndrome with hematuria after transitioning from a regimen of irinotecan, S-1, and bevacizumab to FTD/TPI. Renal biopsy revealed IgA nephropathy with glomerular microangiopathy (GMA). His condition improved with steroid therapy. To our knowledge, this is the first documented case of nephrotic syndrome associated with FTD/TPI. Renal toxicity should be monitored through urinalysis during FTD/TPI treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기